New U-STORM imaging technology lets scientists view molecular structures in subatomic detail — about 1,000 times clearer than traditional dyes — while making the microscope process much simpler. … […]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–The Department of Energy’s Oak Ridge National Laboratory (ORNL) and fusion energy consultancy Rutherford Energy Ventures LP (REV) have officially begun development of a new public-private partnership framework to create shared fusion testbed infrastructure at ORNL. The new consortium model, known as the Fusion Upscaled Leveraged Consortia for… … […]
The company’s cardiovascular business faces new rivals in pulsed field ablation and heart devices. A restructuring plan aims to cut $500 million in annual expenses. … […]
Biogen’s business development team may have been busy in recent years, but CEO Christopher Viehbacher is easing off the acquisitions for a while. … […]
With increased sales of its newer drugs compensating for declining revenues from its multiple sclerosis portfolio, Biogen finally is positioned once again for a “growth story,” CEO Chris Viehbacher said Wednesday during the company’s second quarter earnings call. The company has flipped its 2026 revenue guidance from an expected mid-single… … […]
The visionary PhysioNet platform launched 25 years ago, based on a system developed at MIT in the 1970s. It has become one of the most comprehensive biomedical and clinical data repositories in existence. … […]
SAN DIEGO–(BUSINESS WIRE)– #ArtisBioSolutions–Artis BioSolutions, an advanced therapies company built to streamline the discovery, development, and production of genetic medicines, today announced that both Landmark Bio, its Watertown, Massachusetts-based development and GMP manufacturing operation, and Syngoi, its Bilbao, Spain-based enzymatic synthetic DNA business, will now operate under the Artis BioSolutions… … […]
STOCKHOLM, July 29, 2026 /PRNewswire/ — BioArctic AB’s (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the second quarter 2026, in conjunction with their partner Biogen’s second quarter report. In total, sales of JPY 29.3… … […]
MARLBOROUGH, Mass., July 29, 2026 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.442 billion during the second quarter of 2026, growing 7.5 percent on a reported basis and 7.0 percent on an operational1 and organic2 basis, all compared to the prior… … […]
MONTPELLIER, France & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announces the implementation of the reverse share split of its shares. The reverse share split will result in… … […]
Copyright © 2026 Biotech Networks, LLC
